albumin conjugate is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-22. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
A polyamide is a polymer with repeating units linked by amide bonds. Polyamides occur both naturally and artificially. Examples of naturally occurring polyamides are proteins, such as wool and silk. Artificially made polyamides can be made through step-growth polymerization or solid-phase synthesis yielding materials such as nylons, aramids, and sodium polyaspartate. Synthetic polyamides are commonly used in textiles, automotive industry, carpets, kitchen utensils and sportswear due to their high durability and strength. The transportation manufacturing industry is the major consumer, accounting for 35% of polyamide (PA) consumption.
Bergamot essential oil contains a significant amount of bergapten, a phototoxic substance that gets its name from the bergamot orange. Bergapten, a linear furanocoumarin derived from psoralen, is often found in plants associated with phytophotodermatitis. Bergamot essential oil has a higher concentration of bergapten (3000–3600 mg/kg) than any other Citrus-based essential oil. When bergamot essential oil is applied directly to the skin via a patch test, followed by exposure to ultraviolet light, a concentration-dependent phototoxic effect is observed. However, if the oil is twice rectified (and therefore bergapten-free), no phototoxic response is observed. The International Fragrance Association (IFRA) restricts the use of bergamot essential oil due to its phototoxic effects. Specifically, IFRA recommends that leave-on skin products be limited to 0.4% bergamot oil, which is more restrictive than any other Citrus-based essential oil. Although generally recognized as safe for human consumption, bergamot essential oil contains a significant amount of bergamottin, one of two furanocoumarins believed to be responsible for a number of grapefruit–drug interactions. Furanocoumarin contaminants in some berrgamot oil are removed by distillation before the oil is used as a cosmetic.
As a linear triatomic molecule, CO2 has four vibrational modes as shown in the diagram. In the symmetric and the antisymmetric stretching modes, the atoms move along the axis of the molecule. There are two bending modes, which are degenerate, meaning that they have the same frequency and same energy, because of the symmetry of the molecule. When a molecule touches a surface or touches another molecule, the two bending modes can differ in frequency because the interaction is different for the two modes. Some of the vibrational modes are observed in the infrared (IR) spectrum: the antisymmetric stretching mode at wavenumber 2349 cm−1 (wavelength 4.25 μm) and the degenerate pair of bending modes at 667 cm−1 (wavelength 15.0 μm). The symmetric stretching mode does not create an electric dipole so is not observed in IR spectroscopy, but it is detected in Raman spectroscopy at 1388 cm−1 (wavelength 7.20 μm), with a Fermi resonance doublet at 1285 cm−1. In the gas phase, carbon dioxide molecules undergo significant vibrational motions and do not keep a fixed structure. However, in a Coulomb explosion imaging experiment, an instantaneous image of the molecular structure can be deduced. Such an experiment has been performed for carbon dioxide. The result of this experiment, and the conclusion of theoretical calculations based on an ab initio potential energy surface of the molecule, is that none of the molecules in the gas phase are ever exactly linear. This counter-intuitive result is trivially due to the fact that the nuclear motion volume element vanishes for linear geometries.
Sources: en.wikipedia.org
When an ice road is part of a winter road, as is commonly the case, its design and construction is comprised within the overall road planning, i.e. in conjunction with the over-land segments. Either way, factors that need to be addressed before construction include the following:
Hurley showed tremendous form throughout the TAC Cup, showing his all-round quality for the Northern Knights. He was named All-Australian in 2007 and backed it up with another selection after the 2008 AFL Under 18 Championships and was also selected in the TAC Cup Team of the Year in both seasons. He made his debut against the Port Adelaide Power in round 1, 2009, and was nominated twice as the AFL Rising Star nominee, in round 20 of that season, and round 18 the following year, both times against St Kilda. After his match-winning four goal performance against Hawthorn in round 22, 2009, Leigh Matthews said, "Very few young talls have the physical maturity to match it with their older and stronger opponents, which is why the brilliant early form of young Bomber Michael Hurley is quite amazing." Ahead of the 2010 season, Hurley inherited the famous number 18 guernsey from retired club great Matthew Lloyd. The following four seasons saw Hurley's form fluctuate due to injury and the constant shuffling of his position in the team between both ends of the ground. He averaged 22 goals per season, and spent just as much time playing in the back line on some of the opposition's best key forwards, where his precise kicking and attacking flair out of the back half were noticeable on numerous occasions. The 2014 season brought with it a permanent role for Hurley as a key defender, the position for which he was initially drafted. This newfound positional consistency allowed him to really begin to shine as a footballer.
In November 2024, the US Food and Drug Administration approved PropofolVet Multidose, the first generic propofol injectable emulsion for dogs. PropofolVet Multidose is approved for use as an injectable anesthetic in dogs. PropofolVet Multidose contains the same active ingredient (propofol injectable emulsion) as the approved brand-name drug product, PropoFlo 28, which was first approved on 4 February 2011. In addition, the FDA determined that PropofolVet Multidose contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient.
Sources: en.wikipedia.org
== Side effects == Common and mild side effects of nefazodone reported in clinical trials more often than placebo include dry mouth (25%), sleepiness (25%), nausea (22%), dizziness (17%), blurred vision (16%), weakness (11%), lightheadedness (10%), confusion (7%), and orthostatic hypotension (5%). Rare and serious adverse reactions may include allergic reactions, fainting, painful/prolonged erection, and jaundice. Nefazodone is not especially associated with increased appetite and weight gain. It is also known for having low levels of sexual side effects in comparisons to SSRIs. Nefazodone can cause severe liver damage which may lead to the need for liver transplantation or to death. The incidence of severe liver damage is approximately 1 in every 250,000 to 300,000 patient-years. By the time it started to be withdrawn from the markets in 2003, nefazodone had been associated with at least 53 cases of liver injury (of which 11 led to death) in the United States, and 51 cases of liver toxicity (of which 2 led to transplantation) in Canada. In a 2002 Canadian study of 32 cases, it was noted that databases like those used in the study tended to include only a small proportion of suspected drug reactions. Treatment protocols suggest screening for pre-existing liver disease before initiating nefazodone, and those with known liver disease should not be prescribed nefazodone. If serum AST or serum ALT levels are more than 3 times the upper limit of normal (ULN), treatment should be permanently withdrawn.
== Drug interactions == The additional or sequential use of other nephrotoxic drugs like aminoglycosides, amphotericin B, capreomycin, colistin, polymyxin B, vancomycin, foscarnet, or cisplatin should be closely monitored, or whenever possible completely avoided.
=== Effects === A study performed in 2015 with vervet monkeys (Chlorocebus sabaeus) in St. Kitts, which are homozygous for the apoE4 gene (a condition which in humans is a risk factor for Alzheimer's disease), found that vervets that were administered BMAA orally developed hallmark histopathology features of Alzheimer's disease, including amyloid beta plaques and neurofibrillary tangle accumulation. Vervets in the trial fed smaller doses of BMAA were found to have correlative decreases in these pathology features. Additionally, vervets that were co-administered BMAA with serine were found to have 70% less beta-amyloid plaques and neurofibrillary tangles than those administered BMAA alone, suggesting that serine may be protective against the neurotoxic effects of BMAA. This experiment represents the first in-vivo model of Alzheimer's disease that features both beta-amyloid plaques and hyperphosphorylated tau protein. This study also demonstrates that BMAA, an environmental toxin, can trigger neurodegenerative disease as a result of a gene-environment interaction. Degenerative locomotor diseases have been described in animals grazing on cycad species, fueling interest in a possible link between the plant and the etiology of ALS/PDC. Subsequent laboratory investigations discovered the presence of BMAA. BMAA induced severe neurotoxicity in rhesus macaques, including:
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.